Back to Newsroom

Cyclacel’s CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015

BERKELEY HEIGHTS, N.J., March 20, 2015 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that two abstracts highlighting preclinical data for Cyclacel’s novel cyclin dependent kinase (CDK) inhibitor, CYC065, have been selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2015, being held on April 18 – 22, 2015 in Philadelphia.

Click here to read more